hypoglycemia and glp 1 Glucagon-like peptide-1 GLP-1 for Weight Loss and

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects

Common metabolic factors like excess Others also viewed Explore content categories

Opportunities Outside of Diabetes and Obesity Additional Indications for Exploration Additional Indications for Exploration As new companies look to enter the incretin mimetic space, and existing players seek to expand their portfolios, its increasingly important to look beyond diabetes and obesity

Blood Clots

Reference [1] Wharton, Sean et al